Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor
- 31 August 2007
- journal article
- research article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 120 (2), 416-422
- https://doi.org/10.1016/j.jaci.2007.04.028
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedemaJournal of Allergy and Clinical Immunology, 2006
- Hereditary angioedemaCurrent Opinion in Pediatrics, 2005
- Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedemaTransfusion, 2005
- Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence?International Journal of Clinical Practice, 2005
- Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary AngioedemaJournal of Allergy and Clinical Immunology, 2004
- Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert® P) in hereditary angioedema: a reviewTransfusion and Apheresis Science, 2003
- Does heparin prophylaxis prevent exacerbations of hereditary angioedema?Journal of Allergy and Clinical Immunology, 2002
- Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikreinMolecular Diversity, 1996
- Prekallikrein Activation and High-Molecular-Weight Kininogen Consumption in Hereditary AngioedemaThe New England Journal of Medicine, 1983
- Replacement Therapy in Hereditary AngioedemaThe New England Journal of Medicine, 1980